Immunic Therapeutics (@ImmunicInc) header
Immunic Therapeutics (@ImmunicInc) profile picture

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases.

New York City
Joined January 2018
Photo by Immunic Therapeutics (@ImmunicInc)Photo by Immunic Therapeutics (@ImmunicInc)Photo by Immunic Therapeutics (@ImmunicInc)Photo by Immunic Therapeutics (@ImmunicInc)Photo by Immunic Therapeutics (@ImmunicInc)Photo by Immunic Therapeutics (@ImmunicInc)Photo by Immunic Therapeutics (@ImmunicInc)Photo by Immunic Therapeutics (@ImmunicInc)Photo by Immunic Therapeutics (@ImmunicInc)Photo by Immunic Therapeutics (@ImmunicInc)
Q3/2026 Update: A Conversation with Our CEO 📈 Following our third quarter 2026 financial results and corporate update reported end of last week, #Immunic's CEO, Erik Lundgren, joined @Proactive_US to discuss recent business highlights and what's next for the company. 🎥 Watch the full interview here: bit.ly/3UU8SfZ $IMUX #MSResearch #Biotech
2
3
153
London Week 🇬🇧 #Immunic's Chief Executive Officer Erik Lundgren, President & Chief Operating Officer Jason Tardio and Chief Business Officer Patrick Walsh are in #London this week for investor and partnering meetings around the @Jefferies Global Healthcare Conference 2026. 🤝 They look forward to connecting with the #healthcare, #biotech and #pharma community and sharing $IMUX’s latest developments and outlook. Interested in meeting with us in London? Please feel free to reach out. 📩 #InvestorRelations #BusinessDevelopment #JefferiesHealthcareConference
1
3
5
227
Immunic Therapeutics retweeted
Immunic CEO discusses Q3 highlights and December Phase 3 MS trial readouts @ImmunicInc proactiveinvestors.com/compa… #Immunic #Vidofludimus #Calcium #MS #IMUX
1
1
454
📢 Today, #Immunic reported financial results for the third quarter 2026 and provided a corporate update. Key highlights include: 🔹 Pivotal Phase 3 #ENSURE trials in relapsing #MultipleSclerosis (#MS, #RMS) remain on track, with top-line data expected in December 2026 🔹 Initiation of phase 3 PROTECT-MS trial in progressive MS (#PMS) ongoing, with first-patient-enrolled expected in H1/2027 🔹 Executive leadership team further strengthened with appointments of Chief Data and Digital Officer and Chief People Officer to support regulatory and commercial readiness 👉 Read the full press release: bit.ly/3XlGyUC $IMUX #Biotech
1
2
210
📍 Boston ➡️ New York. That’s a wrap! A busy week for the #Immunic team at the @GuggenheimPtnrs Healthcare Innovation Conference and the @Stifel 2026 Healthcare Conference. 🤝 Thank you to everyone who connected with us, joined our fireside chats and met with our team. We appreciated the great conversations throughout the week! #Immunic $IMUX #Biotech #InvestorRelations
2
6
214
💡 #MSUncovered is back with a closer look at #PIRA (progression independent of relapse activity). PIRA refers to disability worsening in #MultipleSclerosis (#MS) that occurs independently of relapses. Swipe to learn more. $IMUX #Immunic #MSResearch
2
5
190
📰 In a new interview with @PharmaVoice, our CEO Erik Lundgren reflects on the evolution of #MultipleSclerosis (#MS) treatment, the high unmet needs that remain, and #Immunic’s work to develop its investigational lead asset for relapsing and progressive forms of MS. 🗞️ Read the full interview: bit.ly/4szMANf #Neurology #MSReasearch $IMUX
2
4
210
🤝 Meet #Immunic at two investor conferences this week! Our team will be attending: @GuggenheimPtnrs Healthcare Innovation Conference Nov. 9-11 | 📍 Boston 🎤 Fireside Chat: TODAY | 1:00 p.m. ET @Stifel 2026 Healthcare Conference Nov. 10-12 | 📍 New York 🎤 Fireside Chat: Nov 11 | 2:00 p.m. ET We are looking forward to connecting with investors and industry colleagues throughout the week. #Immunic $IMUX #Biotech #InvestorRelations
2
5
253
🧠 A closer look at progressive #MultipleSclerosis (#MS) Thank you to everyone who joined our Virtual Progressive MS R&D Day yesterday, and especially to our guest experts Jiwon Oh, MD, PhD, FRCPC (@UofT) and Maria Pia Sormani, PhD (@UniGenova) for sharing their perspectives and valuable insights. The discussion explored key unmet needs in progressive MS (#PMS), ongoing research into MS progression, and the latest updates from #Immunic’s development program. ▶️ Missed the event? Watch the replay: bit.ly/48BRpw3 #MSResearch #Neurology #ProgressiveMS $IMUX
1
2
198
⏰ Starting today at 12:30 pm ET 🧠 Join #MultipleSclerosis (#MS) guest experts Jiwon Oh, MD, PhD, FRCPC (@UofT) and Maria Pia Sormani, PhD (@UniGenova) alongside #Immunic's management team for our Virtual Progressive #MS (#PMS) R&D Day. 👉 Register: bit.ly/3VOFvMu #MultipleSclerosis #MSResearch #Neurology $IMUX #vidofludimus #IMU838
3
3
204
🧠 What We Learned at the 10th Joint ACTRIMS-ECTRIMS Meeting 2026 🔊 Following #MSToronto2026, @Proactive_US spoke with our CMO Dr. Mike Panzara about key takeaways from this year’s meeting — including our presence at the congress as well as new multiple sclerosis (MS) clinical, biomarker, and preclinical data presented across four poster presentations. 👉 Watch the full interview here: bit.ly/4sDQogb @ACTRIMS @ECTRIMS #MSResearch #Neurology #Immunic $IMUX
2
2
211
🧠 Disability progression remains one of the greatest unmet needs in #MultipleSclerosis (#MS). 🔬This week, our management team will host a Virtual Progressive MS (#PMS) R&D Day featuring experts in MS research Jiwon Oh, MD, PhD, FRCPC (@UofT) and Maria Pia Sormani, PhD (@UniGenova). Don't miss the event on November 5 at 12:30 pm ET. The discussion will cover key unmet needs in PMS and the latest updates from our investigational development program. #MSResearch #Neurology #IMUX #Immunic
2
2
300
📢 Meet the #Immunic team at upcoming investor conferences this November 💼 November 9-11 @GuggenheimPtnrs 3rd Annual Healthcare Innovation Conference (#Boston): Fireside chat on November 9 at 1:00 pm ET and one-on-one investor meetings 🗽 November 10-12 @Stifel 2026 Healthcare Conference (#NewYork): Fireside chat on November 11 at 2:00 pm ET and one-on-one investor meetings 🇬🇧 November 17-18: One-on-one investor meetings in connection with @Jefferies Global Healthcare Conference (#London) Our team is looking forward to connecting with investors and peers throughout the month. 👉 More details: bit.ly/4sCVVUt $IMUX #InvestorRelations #Networking
3
2
267
🎃 The future should not be scary. 👻 For many people living with #MultipleSclerosis (#MS), uncertainty about what the future may hold is not a seasonal fright. It is a daily reality. That's why we are committed to advancing research aimed at helping people with MS look to the future with greater confidence, less uncertainty and more hope. Happy Halloween from the #Immunic team. 🧡
2
5
213
Immunic Therapeutics retweeted
Immunic highlights progressive MS research and Phase 3 outlook at MSToronto2026 @ImmunicInc proactiveinvestors.com/compa… #Immunic #IMUX #MS #Multipleschlerosis #CALLIPER #ENSURE #ACTRIMS #ECTRIMS
2
1
562
#MultipleSclerosis (#MS) is not a single biological story. Its biology has many layers. 🧬 Many things may shape each person’s experience of MS, including their genes, their environment, their resilience, progression beyond relapses, immune cell activity, and inflammation. At #Immunic, we listen first, then act on what patients, their families, and the physicians who treat them share. Our research on #Nurr1 and #DHODH explores different dimensions of the disease because deeper understanding is the first step toward improving everyday life of patients. #MSUncovered $IMUX
1
3
201
📅 Mark your calendar for our Progressive #MultipleSclerosis (#MS) R&D Day on November 5 🧠 Next week, members of #Immunic's management team will be joined by guest experts Jiwon Oh, MD, PhD, FRCPC (@UofT) and Maria Pia Sormani, PhD (@UniGenova) to discuss the key unmet needs in progressive MS (#PMS) and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with #neurodegeneration and MS progression. 🔎 Get all the details here: 6z11edl.s.gy/jahggI #MSResearch $IMUX #neurology #vidofludimus #IMU838
1
2
217
🔬 That’s a wrap on #MSToronto2026! It was a busy and rewarding congress for the #Immunic team last week, filled with scientific exchange, poster presentations and valuable conversations with colleagues and stakeholders from across the #MultipleSclerosis (#MS) community. 🎗️ We presented four posters, with particularly strong engagement during our two paper poster presentations. 🤝 Our booth was busy throughout the meeting, with many opportunities to connect and exchange perspectives at the 10th Joint @ACTRIMS-@ECTRIMS Meeting. Thank you to everyone who stopped by! $IMUX #Neurology #MSResearch
2
7
253
✨ Marking Jaa Roberson’s appointment as the new Chief People Officer of #Immunic, showcased on the #Nasdaq tower in New York City. 🏙️ Welcome again, Jaa, to team $IMUX! We are looking forward to our next phase of growth together. And thank you, @Nasdaq, for the continued support. #NasdaqListed #Leadership
2
5
377
🧠 In our #MSUncovered series, we take a closer look at biological processes relevant to #MultipleSclerosis (#MS). 🔬 One important area of research is #inflammation. In relapsing MS (#RMS), inflammation in specific areas of the brain and spinal cord involves activated immune cells, including T and B cells, and is associated with inflammatory disease activity. When highly active, these cells require large amounts of pyrimidines – essential building blocks that support their function and growth. #DHODH is a key enzyme in pyrimidine synthesis. Because DHODH supports this process in highly active immune cells, investigating DHODH inhibition is of interest as a way to regulate immune-cell activity associated with inflammation in relapsing MS. 🎗️ Each new discovery helps build a more complete picture of the disease and the challenges people living with MS continue to face. #Immunic $IMUX #MSResearch
1
2
7
328